Status:
COMPLETED
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
i3 Innovus
Conditions:
Gastroesophageal Reflux Disease (GERD)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who ...
Eligibility Criteria
Inclusion
- At least 6 month history of GERD symptoms
- Treated with unchanged optimized PPI treatment for any GERD indication during a consecutive 4 week period
- Remaining GERD symptoms despite optimized PPI treatment
- Able to read and write in US English, and able to comply with study requirements
Exclusion
- Patients that have not experienced any GERD symptom improvement at all during PPI treatment
- Involvement in the planning or conduct of the study
- Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
552 Patients enrolled
Trial Details
Trial ID
NCT00795093
Start Date
November 1 2008
End Date
January 1 2010
Last Update
May 11 2010
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Leeds, Alabama, United States
2
Research Site
Pheonix, Arizona, United States
3
Research Site
Tucson, Arizona, United States
4
Research Site
Concord, California, United States